Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) had its target price lowered by stock analysts at Piper Sandler from $16.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Get Perspective Therapeutics alerts:View Our Latest Research Report on CATXPerspective Therapeutics Stock PerformanceShares of NYSEAMERICAN CATX opened at $3.00 on Tuesday. Perspective Therapeutics Company Profile(Get Free Report)Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. Further ReadingReceive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.